S&P 500   4,272.49 (-0.05%)
DOW   33,557.17 (+0.02%)
QQQ   354.41 (-0.18%)
AAPL   169.75 (-0.40%)
MSFT   311.57 (-0.39%)
META   298.02 (+0.09%)
GOOGL   130.47 (-0.05%)
AMZN   124.44 (-1.22%)
TSLA   239.44 (-0.44%)
NVDA   424.90 (+0.05%)
NIO   8.46 (+0.59%)
BABA   85.05 (-1.32%)
AMD   98.20 (+0.13%)
T   14.82 (-0.34%)
F   12.32 (-0.56%)
MU   66.36 (-2.71%)
CGC   0.88 (-0.69%)
GE   111.00 (+0.10%)
DIS   79.91 (+0.01%)
AMC   7.56 (-0.13%)
PFE   32.09 (-0.03%)
PYPL   57.30 (-0.07%)
NFLX   377.00 (-0.16%)
S&P 500   4,272.49 (-0.05%)
DOW   33,557.17 (+0.02%)
QQQ   354.41 (-0.18%)
AAPL   169.75 (-0.40%)
MSFT   311.57 (-0.39%)
META   298.02 (+0.09%)
GOOGL   130.47 (-0.05%)
AMZN   124.44 (-1.22%)
TSLA   239.44 (-0.44%)
NVDA   424.90 (+0.05%)
NIO   8.46 (+0.59%)
BABA   85.05 (-1.32%)
AMD   98.20 (+0.13%)
T   14.82 (-0.34%)
F   12.32 (-0.56%)
MU   66.36 (-2.71%)
CGC   0.88 (-0.69%)
GE   111.00 (+0.10%)
DIS   79.91 (+0.01%)
AMC   7.56 (-0.13%)
PFE   32.09 (-0.03%)
PYPL   57.30 (-0.07%)
NFLX   377.00 (-0.16%)
S&P 500   4,272.49 (-0.05%)
DOW   33,557.17 (+0.02%)
QQQ   354.41 (-0.18%)
AAPL   169.75 (-0.40%)
MSFT   311.57 (-0.39%)
META   298.02 (+0.09%)
GOOGL   130.47 (-0.05%)
AMZN   124.44 (-1.22%)
TSLA   239.44 (-0.44%)
NVDA   424.90 (+0.05%)
NIO   8.46 (+0.59%)
BABA   85.05 (-1.32%)
AMD   98.20 (+0.13%)
T   14.82 (-0.34%)
F   12.32 (-0.56%)
MU   66.36 (-2.71%)
CGC   0.88 (-0.69%)
GE   111.00 (+0.10%)
DIS   79.91 (+0.01%)
AMC   7.56 (-0.13%)
PFE   32.09 (-0.03%)
PYPL   57.30 (-0.07%)
NFLX   377.00 (-0.16%)
S&P 500   4,272.49 (-0.05%)
DOW   33,557.17 (+0.02%)
QQQ   354.41 (-0.18%)
AAPL   169.75 (-0.40%)
MSFT   311.57 (-0.39%)
META   298.02 (+0.09%)
GOOGL   130.47 (-0.05%)
AMZN   124.44 (-1.22%)
TSLA   239.44 (-0.44%)
NVDA   424.90 (+0.05%)
NIO   8.46 (+0.59%)
BABA   85.05 (-1.32%)
AMD   98.20 (+0.13%)
T   14.82 (-0.34%)
F   12.32 (-0.56%)
MU   66.36 (-2.71%)
CGC   0.88 (-0.69%)
GE   111.00 (+0.10%)
DIS   79.91 (+0.01%)
AMC   7.56 (-0.13%)
PFE   32.09 (-0.03%)
PYPL   57.30 (-0.07%)
NFLX   377.00 (-0.16%)
NASDAQ:GLTO

Galecto (GLTO) Competitors

$0.63
-0.07 (-9.33%)
(As of 09:00 AM ET)
Compare
Today's Range
$0.63
$0.63
50-Day Range
$0.56
$3.17
52-Week Range
$0.54
$3.70
Volume
175,446 shs
Average Volume
279,348 shs
Market Capitalization
$17.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.60

GLTO vs. RNXT, KZIA, ONTX, NHWK, APRE, TNXP, CNTX, NNVC, BFRG, and CALC

Should you be buying Galecto stock or one of its competitors? The main competitors of Galecto include RenovoRx (RNXT), Kazia Therapeutics (KZIA), Onconova Therapeutics (ONTX), NightHawk Biosciences (NHWK), Aprea Therapeutics (APRE), Tonix Pharmaceuticals (TNXP), Context Therapeutics (CNTX), NanoViricides (NNVC), Bullfrog AI (BFRG), and CalciMedica (CALC). These companies are all part of the "pharmaceutical preparations" industry.

Galecto vs.

Galecto (NASDAQ:GLTO) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings.

Galecto has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, RenovoRx has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

Galecto currently has a consensus target price of $7.60, suggesting a potential upside of 988.83%. RenovoRx has a consensus target price of $13.00, suggesting a potential upside of 900.00%. Given Galecto's higher probable upside, analysts clearly believe Galecto is more favorable than RenovoRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galecto
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57
RenovoRx
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

29.4% of Galecto shares are held by institutional investors. Comparatively, 2.3% of RenovoRx shares are held by institutional investors. 12.1% of Galecto shares are held by insiders. Comparatively, 9.0% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Galecto had 2 more articles in the media than RenovoRx. MarketBeat recorded 4 mentions for Galecto and 2 mentions for RenovoRx. RenovoRx's average media sentiment score of 1.44 beat Galecto's score of 0.64 indicating that RenovoRx is being referred to more favorably in the news media.

Company Overall Sentiment
Galecto Positive
RenovoRx Positive

Galecto's return on equity of -90.21% beat RenovoRx's return on equity.

Company Net Margins Return on Equity Return on Assets
GalectoN/A -90.21% -73.98%
RenovoRx N/A -210.91%-144.42%

RenovoRx is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GalectoN/AN/A-$61.62M-$2.01-0.35
RenovoRxN/AN/A-$9.89M-$1.05-1.24

Galecto received 25 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 60.00% of users gave Galecto an outperform vote while only 35.71% of users gave RenovoRx an outperform vote.

CompanyUnderperformOutperform
GalectoOutperform Votes
30
60.00%
Underperform Votes
20
40.00%
RenovoRxOutperform Votes
5
35.71%
Underperform Votes
9
64.29%

Summary

Galecto beats RenovoRx on 11 of the 15 factors compared between the two stocks.


Get Galecto News Delivered to You Automatically

Sign up to receive the latest news and ratings for GLTO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GLTO vs. The Competition

MetricGalectoPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$18.92M$5.63B$4.37B$6.23B
Dividend YieldN/A2.67%5.93%9.41%
P/E Ratio-0.356.35123.9912.94
Price / SalesN/A154.652,978.1156.56
Price / CashN/A22.3692.78100.00
Price / Book0.293.783.724.61
Net Income-$61.62M$195.18M$122.44M$186.23M
7 Day Performance20.59%-1.70%-1.74%-2.47%
1 Month Performance19.30%-7.91%-3.98%-5.16%
1 Year Performance-64.75%9.45%10.46%5.69%

Galecto Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RNXT
RenovoRx
2.1971 of 5 stars
$1.50
+0.7%
$13.00
+766.7%
-29.7%$16.04MN/A-1.4310Short Interest ↓
Positive News
Gap Up
KZIA
Kazia Therapeutics
2.1971 of 5 stars
$1.04
+4.0%
$2.00
+92.3%
-7.2%$16.34M$20,000.000.002,021Short Interest ↓
Gap Down
ONTX
Onconova Therapeutics
2.0485 of 5 stars
$0.79
-2.5%
$11.00
+1,295.1%
-19.4%$16.54M$230,000.00-0.7916Short Interest ↑
Gap Down
NHWK
NightHawk Biosciences
0 of 5 stars
$0.59
+1.7%
N/A-69.8%$15.47M$6.38M-0.3077News Coverage
Gap Up
APRE
Aprea Therapeutics
2.3792 of 5 stars
$4.10
-0.2%
$14.50
+253.7%
-69.9%$15.33MN/A-0.749
TNXP
Tonix Pharmaceuticals
2.3891 of 5 stars
$0.85
-1.2%
$8.00
+836.8%
-78.0%$15.17MN/A-0.06117Positive News
Gap Up
CNTX
Context Therapeutics
1.9864 of 5 stars
$0.94
-1.1%
$4.00
+325.5%
+10.3%$15.01MN/A-0.809Short Interest ↑
News Coverage
NNVC
NanoViricides
0 of 5 stars
$1.28
flat
$5.25
+310.2%
-9.4%$14.90MN/A-2.1717Analyst Report
News Coverage
BFRG
Bullfrog AI
0 of 5 stars
$2.88
flat
N/AN/A$17.54M$10,000.000.004Short Interest ↑
Gap Down
CALC
CalciMedica
0 of 5 stars
$3.10
-2.2%
N/AN/A$17.55MN/A0.0014Positive News
Gap Down

Related Companies and Tools

This page (NASDAQ:GLTO) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -